Free shipping on all orders over $ 500

JTE 607 dihydrochloride

Cat. No. M6852
JTE 607 dihydrochloride Structure
Synonym:

JTE-607 2HCl

Size Price Availability Quantity
2mg USD 70  USD70 In stock
5mg USD 100  USD100 In stock
10mg USD 185  USD185 In stock
25mg USD 355  USD355 In stock
50mg USD 665  USD665 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

JTE 607 dihydrochloride is a cytokine release inhibitor. JTE 607 dihydrochloride inhibits production of IL-1β, IL-8, IL-6, IL-10 and TNFα from LPS-stimulated PBMCs with IC50 values are 5.9, 7.3, 8.8, 9.1 and 11.0 nM, respectively. JTE 607 dihydrochloride reduces proinflammatory cytokine-release and attenuates lung permeability in a rat lung injury model. JTE-607 induces apoptosis in leukemia cells in vitro and prolongs survival in a mouse leukemia model.

Chemical Information
Molecular Weight 597.36
Formula C25H31Cl2N3O5.2HCl
CAS Number 188791-09-5
Solubility (25°C) DMSO 100 mg/mL
Water ≥ 20 mg/mL
Storage -20°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Aliagas-Martin, et al. J Med Chem. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Related IL Receptor/Related Products
HB0017

HB0017 is a monoclonal antibody that targets interleukin-17 (IL-17) and selectively binds IL-17A, thereby preventing IL-1717A from binding to its receptor.

Rademikibart

Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases.

Stapokibart

Stapokibart is a humanized monoclonal antibody targeting IL-4Rα that blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit, IL-4Rα. Stapokibart is able to interact with IL-4Rα in humans, cynomolgus monkeys, and rats, and can be used in atopic dermatitis research.

Erepdekinra

Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist.

AF12198

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM).

  Catalog
Abmole Inhibitor Catalog




Keywords: JTE 607 dihydrochloride, JTE-607 2HCl supplier, IL Receptor/Related, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.